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2172ReplyEthnic Diversity and
Immunological Barriers
in Heart TransplantationWe appreciate the interest shown by Dr. Deutsch and colleagues in
our work (1) and their thoughtful comments regarding outcomes
after heart transplantation (HT) as a function of race, panel reactive
antibody (PRA) burden, and sensitization. We agree that existing
data suggest the superiority of tacrolimus-based immunosuppres-
sive regimens, particularly in black patients (2), with the proviso
that blacks often require higher tacrolimus doses to reach thera-
peutic trough concentrations (3,4). Importantly, a recent analysis
from the United Network for Organ Sharing (UNOS) database
shows that a higher proportion of black HT recipients were
receiving tacrolimus therapy than whites in recent years (5). We did
not investigate differences in the use of various induction strategies,
but previous studies have shown that induction immunosuppres-
sion using lymphocytolytic agents in the early perioperative period
was associated with a survival beneﬁt in younger black patients
with 4 human leukocyte antigen (HLA) mismatches (6).
Dr. Deutsch and colleagues also correctly noted the insensitivity
of standard Centers for Disease Control and Prevention (CDC)-
based PRA testing compared to newer solid-phase or microsphere-
based assays that have been increasingly used since the mid-1990s
(7). Speciﬁc information regarding the technique used for
HLA antibody detection was however not available in the UNOS
database. To partially circumvent this issue, we limited our analysis
to transplantations that were performed after 2000, hoping
to capture the PRA results that were largely based on newer
HLA platforms. Recent consensus guidelines in this regard pub-
lished by the Transplantation Society provide state-of-the-art
guidance in the clinical application of newer methods for HLA
antibody detection when used in conjunction with conventional
methods (8).
Clinical studies that further investigate the results of our study
incorporating speciﬁc information on the various induction and
maintenance immunosuppressive regimens used and the immu-
nologic assays performed for assessment of sensitization status will
be of great interest.*Alanna A. Morris, MD
Javed Butler, MD, MPH
*Division of Cardiology
Emory University School of Medicine
1462 Clifton Road Suite 520
Atlanta, Georgia 30322
E-mail: aamorr3@emory.edu
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REFERENCES
1. Morris AA, Cole RT, Veledar E, et al. Inﬂuence of race/ethnic differ-
ences in pre-transplant panel reactive antibody on outcomes in heart
transplant recipients. J Am Coll Cardiol 2013;62:2308–15.
2. Mehra MR, Uber PA, Scott RL, Park MH. Ethnic disparity in clinical
outcome after heart transplantation is abrogated using tacrolimus andmycophenolate mofetil-based immunosuppression. Transplantation
2002;74:1568–73.
3. Yasuda S, Zhang L, Huang S-M. The role of ethnicity in variability in
response to drugs: focus on clinical pharmacology studies. Clin Phar-
macol Ther 2008;84:417–23.
4. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1
Single nucleotide polymorphisms on the pharmacokinetics and phar-
macodynamics of calcineurin inhibitors: part I. Clin Pharmacokinetics
2010;49:141–75.
5. Singh TP, Almond C, Givertz MM, Piercey G, Gauvreau K. Improved
survival in heart transplant recipients in the United States: racial dif-
ferences in era effect. Circulation 2011;4:153–60.
6. Higgins R, Kirklin JK, Brown RN, et al. To induce or not to induce: do
patients at greatest risk for fatal rejection beneﬁt from cytolytic induction
therapy? J Heart Lung Transplant 2005;24:392–400.
7. Bray RA, Tarsitani C, Gebel HM, Lee J-H. Clinical cytometry and
progress in HLA antibody detection. In: Zbigniew Darzynkiewicz
EHAOWT, Donald W, editors. Methods in Cell Biology. New York,
NY: Academic Press; 2011:285–310.
8. Tait BD, Susal C, Gebel HM, et al. Consensus guidelines on the testing
and clinical management issues associated with hla and non-HLA an-
tibodies in transplantation. Transplantation 2013;95:19–47.Carotid Plaque
Hemorrhage on
Magnetic Resonance
Imaging and Recurrent
Cerebrovascular EventsWe read with interest the recent report by Saam et al. (1) describing
the predictive value of magnetic resonance imaging–detected carotid
plaque hemorrhage for cerebrovascular events. They undertook a
meta-analysis of the published research through September 2012
assuming a constant event rate during follow-up to derive an esti-
mated hazard ratio for magnetic resonance imaging–detected carotid
plaque hemorrhage of 5.69 (95% conﬁdence interval: 2.98 to 10.87).
Unfortunately, the investigators missed our most recent work (2),
which included a meta-analysis and presented new combined data
from 3 previous studies (3–5) with increased length of follow-up.
We derived a broadly similar conclusion but preferred to report
the odds ratio, because the assumption of a constant event rate is
unlikely to be true. We found no signiﬁcant heterogeneity between
the studies included (p ¼ 0.26, I2 ¼ 22.3%). The “trim and ﬁll”
method (6) was applied to calculate the number of studies that
would be required to return the plot to “symmetry” and remove
publication bias and to provide a revised estimated odds ratio.
We also note that an assumption was made by the investigators
to treat the results from Kume et al. (7) as asymptomatic, despite
the investigators’ acknowledging that almost one third were
symptomatic. It would seem, without further data from Kume
et al.’s study, that these results should only be included in a com-
bined meta-analysis for the symptomatic and asymptomatic carotid
arteries and should be excluded from the meta-regression.
Repeating the meta-analysis including the data from Kume et al.,
we found an odds ratio at 7.87 (95% conﬁdence interval: 4.7 to 13),
but no heterogeneity. Whether or not symptom status affects the
relative risk remains unclear, as only 2 studies reported on
asymptomatic patients only.
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2173Interestingly, in the past few months, a number of further
conﬁrmatory studies have been published, highlighting the
importance of this area of research but unsuitable for inclusion in
a meta-analysis. More studies are needed for meta-regression to
establish effects of symptoms and degree of stenosis. We strongly
welcome the suggestion of Saam et al. (1) of harmonization of
future studies with respect to randomized controlled trials of this
noninvasive marker for stroke and transient ischemic attack.*Akram A. Hosseini
Richard J. Simpson, MSc
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Neurosurg Rev 2010;33:419–30.ReplyCarotid Plaque Hemorrhage
on Magnetic Resonance
Imaging and Recurrent
Cerebrovascular EventsWe thank Dr. Hosseini and colleagues for their thoughtful
comments on our recently published meta-analysis on the predic-
tive value of carotid plaque hemorrhage by magnetic resonanceimaging on cerebrovascular events (1). We are delighted to observe
recently emerging research efforts providing ever more insights
into the prognostic role of carotid plaque features by magnetic
resonance imaging (2), including the work by Hosseini et al. (3)
and others (4,5), which was published after the completion of
our report.
Dr. Hosseini and colleagues suggest that utilization of odds
ratios might be preferable to hazard ratios (HR) as a means of
pooling prognostic data, given that the event rate may not be
constant. Although both estimates represent risks associated with
distinct ﬁndings (i.e., plaque hemorrhage on magnetic resonance
imaging), we agree that the most appropriate application of each
is dependent on the included source data. In contrast to odds
ratios, however, HRs accommodate differences in observation
times between studies and censoring and thus are particularly
suited for time-to-event analyses (6). In fact, differences in
observation times and pattern of censoring were likely to occur in
our setting given a median follow-up time of 19.6 months with a
range of 1.1 to 38.2 months. Thus, the majority of pooled source
populations reported HRs as their primary risk estimate, clearly
relying on the proportional hazards assumption over time. In our
opinion, both markers of risk suffer from inherent limitations,
and future efforts should include more complex statistical ap-
proaches such as individual patient–based meta-analyses, which
may be more appropriate to determine differences among patient
subgroups.
Dr. Hosseini and colleagues argue that the study by Kume et al.
(7) should not have been included in the meta-regression analysis
comparing differences between symptomatic and asymptomatic
subjects. A priori, this study was categorized as an asymptomatic
population because of the larger proportion of asymptomatic sub-
jects (68%), but we agree that this assumption is debatable and may
warrant speciﬁc subanalysis. To accommodate the comments
of Dr. Hosseini and colleagues, we excluded the data from that
study (7) and incorporated the additional ﬁndings of studies pub-
lished after the completion of our meta-analysis in symptomatic (3)
and asymptomatic (4) subjects. Another recent study in asymp-
tomatic subjects was not included, because the authors did not use
fat suppression on T1-weighted sequences, which was a pre-
deﬁned inclusion requirement in our meta-analysis (5). Although
HRs for the predictive value of carotid plaque hemorrhage on
cerebrovascular events were higher in symptomatic (HR: 11.60;
95% conﬁdence interval: 2.88 to 46.63; p ¼ 0.0006) compared
with asymptomatic (HR: 4.44; 95% conﬁdence interval: 2.54 to
7.76; p < 0.0001) subjects, the interaction between the 2 groups
did not reach statistical signiﬁcance. The I2 value as well as visual
inspection of the forest plot indicated heterogeneity similar to
our initial analysis (I2 ¼ 55.8%). Thus, our updated ﬁndings are
in line with Hosseini et al.’s observation that, on the basis of
currently available data, no deﬁnite conclusions can be drawn on
predictive value in symptomatic compared with asymptomatic
patients, and further, more dedicated research is required. It
will be interesting to observe whether known underlying differ-
ences in the biology of carotid lesions in symptomatic and
asymptomatic subjects (8) will eventually translate into clear dif-
ferences in risk.*Tobias Saam, MD
Holger Hetterich, MD
Verena S. Hoffmann, PhD
Fabian Bamberg, MD, MPH
